(±)-(N-(5-methyl-4-phenyl-thiazol-2-yl)-6-(2-phenyl-pyrrolidin-1-yl))-nicotinamide | 1224870-14-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (±)-(N-(5-methyl-4-phenyl-thiazol-2-yl)-6-(2-phenyl-pyrrolidin-1-yl))-nicotinamide
• 英文别名: (+/-)-N-(5-methyl-4-phenyl-thiazol-2-yl)-6-(2-phenyl-pyrrolidin-1-yl)-nicotinamide；N-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-6-(2-phenylpyrrolidin-1-yl)pyridine-3-carboxamide
• CAS: 1224870-14-7
• 化学式: C₂₆H₂₄N₄OS
• 分子量: 440.569
• InChiKey: BMMFQXMHSMGBTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20100113782A1

  公开（公告）日：2010-05-06

  Provided herein are compounds of the formula (I): were R1 is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a 4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了化合物的公式（I）：其中R1为苯基，R2为氢、卤素或低碳烷基，X为碳或氮，R3为异喹啉基、氨基或含有4至6个成员的杂环烷基环，并且其药学上可接受的盐，这些化合物作为DGAT抑制剂具有活性，因此可用于治疗与三酸甘油酯异常代谢相关的疾病，例如肥胖症、2型糖尿病和代谢综合征。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：EP2350311B1

  公开（公告）日：2013-12-25
• US8324385B2
  申请人：——

  公开号：US8324385B2

  公开（公告）日：2012-12-04
• [EN] DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：VIA PHARMACEUTICALS INC

  公开号：WO2010056506A1

  公开（公告）日：2010-05-20

  Provided herein are compounds of the formula (I): were Rl is phenyl, R2 is hyrogen, halogen or lower alkyl,X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a-4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides, such as, for example, obesity, type Il diabetes mellitus and metabolic syndrome.